|
1857
|
AP 24534
|
BCR-ABL kinase inhibitor (including T315I mutation) |
€80.00
|
|
2757
|
Asciminib
|
Potent and selective allosteric BCR-ABL1 inhibitor |
Recently added
|
€120.00
|
|
2005
|
ASP 3026
|
Inhibitor of the oncogenic fusion kinase EML4-ALK |
€80.00
|
|
1392
|
Dasatinib
|
Bcr-Abl and Src tyrosine kinase inhibitor |
€90.00
|
|
2123
|
DCC 2036
|
An orally active Bcr-ABL inhibitor |
€125.00
|
|
1882
|
GNF 2
|
Inhibitor of Bcr-Abl tyrosine kinase |
€110.00
|
|
1394
|
Imatinib mesylate
|
Bcr-Abl, c-KIT and PDGFR kinase inhibitor |
€60.00
|
|
2121
|
INNO 406
|
Dual Bcr-Abl and Lyn kinase inhibitor |
€85.00
|
|
2294
|
KRCA 0008
|
Potent and selective dual ALK/ACK1 inhibitor with good drug-like properties |
€95.00
|
|
1396
|
Nilotinib
|
BCR-ABL inhibitor |
€50.00
|
|
3168
|
Nilotinib hydrochloride
|
BCR-ABL inhibitor |
€70.00
|
|
1416
|
NVP-TAE684
|
NPM-ALK inhibitor |
€50.00
|
|
1137
|
PD180970
|
Bcr-Abl tyrosine kinase inhibitor (p210 specific) |
€120.00
|
|
1407
|
SKI 606
|
Bcr-Abl and Src tyrosine kinase inhibitor |
€75.00
|